Advances in ophthalmic drug delivery technology for postoperative management after cataract surgery

Lee, Kangmin; Lee, Gahye; Lee, Soomin; Park, Keun

doi:10.1080/17425247.2022.2109624

Cited by 4 publications

(4 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A push to better understand mechanisms that contribute to the acute to chronic pain transition, molecules involved in the maintenance of chronic pain, and diagnostic strategies to identify neuropathic pain will hopefully lead to improved treatment strategies that deliver personalized targeted therapies. As exploration continues in addressing ocular itch and pain, further characterization of these abnormal sensations can help guide diagnostics and treatment strategies [10,30,31,44].…”

Section: Discussionmentioning

confidence: 99%

Ocular surface itch and pain: key differences and similarities between the two sensations

Raolji

Kumar

2023

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review To review the pathophysiology and treatment of ocular itch and pain, encompassing nociceptive and neuropathic categories. Recent findings Ocular itch and pain are sensations that arise from activation of ocular surface polymodal nerves. Nociceptive itch, commonly comorbid with ocular pain complaints, is mainly driven by a histamine-mediated type 1 hypersensitivity reaction. Beyond topical therapy, novel drug delivery systems are being explored to improve ocular residence time of nonsteroidal anti-inflammatory drugs (NSAIDs) and antihistamines. Nociceptive ocular pain can be driven by a variety of factors. Treatment focuses on addressing the causative sources of pain. Neuropathic ocular itch and pain are driven by nerve damage and dysfunction and as such, topical and oral neuromodulation have been explored as treatments. Oral neuromodulators include alpha 2 delta ligands, tricyclic antidepressants (TCAs), and low dose naltrexone. Novel therapies are being evaluated for both modalities such as difelikefalin (κ-opioid receptor agonist) for neuropathic itch and libvatrep (transient receptor potential vanilloid 1 antagonist) for neuropathic pain. Summary Both ocular itch and pain can be driven by nociceptive and/or neuropathic mechanisms. Identifying contributors to abnormal ocular sensations is vital for precise medical care. Novel therapeutics for these conditions aim to improve patient outcomes and quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Ocular surface itch and pain: key differences and similarities between the two sensations

Raolji

Kumar

2023

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…131 To modify drug pharmacokinetics, the initial burst of drug release can be reduced by coupling the drug to the nanocarrier. 132 Therefore, ideal drug nanocarriers should have an appropriate size, surface charge, and hydrophilic or hydrophobic properties, as well as good biocompatibility and degradability to enhance drug utilization and reduce cytotoxicity.…”

Section: Physicochemical Properties and Surface Engineering Of Catara...mentioning

confidence: 99%

Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment

Chen,

Ye,

Chen

et al. 2024

IJN

View full text Add to dashboard Cite

Cataract is a leading cause of blindness globally, and its surgical treatment poses a significant burden on global healthcare. Pharmacologic therapies, including antioxidants and protein aggregation reversal agents, have attracted great attention in the treatment of cataracts in recent years. Due to the anatomical and physiological barriers of the eye, the effectiveness of traditional eye drops for delivering drugs topically to the lens is hindered. The advancements in nanomedicine present novel and promising strategies for addressing challenges in drug delivery to the lens, including the development of nanoparticle formulations that can improve drug penetration into the anterior segment and enable sustained release of medications. This review introduces various cutting-edge drug delivery systems for cataract treatment, highlighting their physicochemical properties and surface engineering for optimal design, thus providing impetus for further innovative research and potential clinical applications of anti-cataract drugs.

show abstract

“…Intraocular and External Ophthalmic Implants and Biopolymers: The utilization of novel intraocular and external ophthalmic implants, polymers, and nanotechnology is becoming increasingly important for enhancing postoperative drug delivery in cataract surgery [ 166 ]. Recent advancements in this area include the application of supercritical CO 2 to load gatifloxacin into hydrophobic foldable intraocular lenses, offering a solvent-free approach to reduce the risk of postoperative endophthalmitis [ 167 ].…”

Section: Biopolymeric Drugs Delivery Systemsmentioning

confidence: 99%

Biopolymeric Innovations in Ophthalmic Surgery: Enhancing Devices and Drug Delivery Systems

Wu,

Khan,

Liao

et al. 2024

Polymers

View full text Add to dashboard Cite

The interface between material science and ophthalmic medicine is witnessing significant advances with the introduction of biopolymers in medical device fabrication. This review discusses the impact of biopolymers on the development of ophthalmic devices, such as intraocular lenses, stents, and various prosthetics. Biopolymers are emerging as superior alternatives due to their biocompatibility, mechanical robustness, and biodegradability, presenting an advance over traditional materials with respect to patient comfort and environmental considerations. We explore the spectrum of biopolymers used in ophthalmic devices and evaluate their physical properties, compatibility with biological tissues, and clinical performances. Specific applications in oculoplastic and orbital surgeries, hydrogel applications in ocular therapeutics, and polymeric drug delivery systems for a range of ophthalmic conditions were reviewed. We also anticipate future directions and identify challenges in the field, advocating for a collaborative approach between material science and ophthalmic practice to foster innovative, patient-focused treatments. This synthesis aims to reinforce the potential of biopolymers to improve ophthalmic device technology and enhance clinical outcomes.

show abstract

Advances in ophthalmic drug delivery technology for postoperative management after cataract surgery

Cited by 4 publications

References 138 publications

Ocular surface itch and pain: key differences and similarities between the two sensations

Ocular surface itch and pain: key differences and similarities between the two sensations

Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment

Biopolymeric Innovations in Ophthalmic Surgery: Enhancing Devices and Drug Delivery Systems

Contact Info

Product

Resources

About